1. Home
  2. TLS vs DCTH Comparison

TLS vs DCTH Comparison

Compare TLS & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Telos Corporation

TLS

Telos Corporation

HOLD

Current Price

$5.14

Market Cap

463.8M

Sector

Technology

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$10.10

Market Cap

289.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TLS
DCTH
Founded
1969
1988
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
463.8M
289.2M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
TLS
DCTH
Price
$5.14
$10.10
Analyst Decision
Buy
Strong Buy
Analyst Count
5
5
Target Price
$7.75
$22.60
AVG Volume (30 Days)
938.1K
737.7K
Earning Date
11-10-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.03
Revenue
$144,400,000.00
$79,603,000.00
Revenue This Year
$52.27
$131.97
Revenue Next Year
$20.44
$38.84
P/E Ratio
N/A
$288.65
Revenue Growth
17.44
251.54
52 Week Low
$1.83
$8.12
52 Week High
$8.36
$18.23

Technical Indicators

Market Signals
Indicator
TLS
DCTH
Relative Strength Index (RSI) 36.41 56.71
Support Level $5.33 $9.84
Resistance Level $6.40 $10.28
Average True Range (ATR) 0.29 0.44
MACD -0.02 0.07
Stochastic Oscillator 0.39 61.43

Price Performance

Historical Comparison
TLS
DCTH

About TLS Telos Corporation

Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: